THOUSAND OAKS, Calif., Nov. 3 /PRNewswire-FirstCall/ -- Amgen (Nasdaq: AMGN) today announced that it will hold its Business Review Meeting on Friday, Nov. 7, 2008 at the Millennium Broadway Hotel, 145 West 44th Street, New York City, beginning at 8 a.m. Eastern Time. Participating in the meeting will be Kevin Sharer, chairman and CEO, Roger M. Perlmutter, M.D., Ph.D., executive vice president, Research and Development, George Morrow, executive vice president, Global Commercial Operations, Robert Bradway, executive vice president and CFO, and other members of Amgen's senior management team.
Live video of the meeting will be simultaneously broadcast over the Internet and will be available to members of the news media, investors and the general public.
The webcast of the conference, as with other selected presentations regarding developments in Amgen's business given by management at certain investor and medical conferences, can be found on Amgen's Web site, http://www.amgen.com, under Investors. Information regarding presentation times, webcast availability, and webcast links are noted on Amgen's Investor Relations Events Calendar. The webcast will be archived and available for replay 72 hours after the event.
Amgen discovers, develops, manufactures and delivers innovative human
therapeutics. A biotechnology pioneer since 1980, Amgen was one of the
first companies to realize the new science's promise by bringing safe and
effective medicines from lab, to manufacturing plant, to patient. Amgen
therapeutics have changed the practice of medicine, helping millions of
people around the world in the fight against cancer, kidney disease,
rheumatoid arthritis, and other serious illnesses. With a deep and broad
pipeline of potential new medicines, Amgen remains committed to advancing
science to dramatically improve people's lives. To learn more about our
pioneering science and our vital medicines, visit http://www.amgen.com.
CONTACT: Amgen, Thousand Oaks
David Polk, 805-447-4613 (media)
Arvind Sood, 805-447-1060 (investors)
Copyright©2008 PR Newswire.
All rights reserved